<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127423</url>
  </required_header>
  <id_info>
    <org_study_id>2016-828</org_study_id>
    <nct_id>NCT03127423</nct_id>
  </id_info>
  <brief_title>Comparison Between One-stop Hybrid Ablation and Thoracoscopic Surgical Ablation for Refactory Atrial Fibrillation</brief_title>
  <official_title>Comparison Between One-stop Hybrid Ablation and Thoracoscopic Surgical Ablation for Refactory Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <brief_summary>
    <textblock>
      Previous evidence indicated that the outcomes of both video-assisted thoracoscopic surgical
      ablation and percutaneous radiofrequency ablation therapy for persistent atrial fibrillation
      (AF) were unsatisfied. Recently, hybrid ablation therapy for AF had encouraging outcomes.
      However, there were no randomized, controlled clinical studies to prove the effectiveness of
      this new strategy. This study is aimed to compare the outcomes of hybrid ablation with
      video-assisted thoracoscopic surgical ablation for persistent AF with enlarged left atrium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to compare the outcomes of hybrid ablation with video-assisted
      thoracoscopic surgical ablation for persistent AF with enlarged left atrium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate without any recurrence of AF</measure>
    <time_frame>12 months</time_frame>
    <description>Sinus rhythm, without detections of atrial arrhythmias (episodes longer than 30 seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall cost</measure>
    <time_frame>12 months</time_frame>
    <description>All the costs in-patient and out-patient related to AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of AF</measure>
    <time_frame>At 3-month, 6-month, and 12-month after intervention</time_frame>
    <description>Burden of AF according to Tele-ECG-Card lasting for one week</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Hybrid ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracoscopic surgical ablation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hybrid ablation</intervention_name>
    <description>This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.</description>
    <arm_group_label>Hybrid ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracoscopic surgical ablation</intervention_name>
    <description>This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.</description>
    <arm_group_label>Thoracoscopic surgical ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with at least one anti-arrhythmic drugs

          -  Persistent AF lasting more than 1 year or with a left atrial diameter&gt;50mm

        Exclusion Criteria:

          -  Previous percutaneous catheter ablation or surgical ablation

          -  Presence of significant structural heart disease (dilated cardiomyopathy, hypertrophic
             cardiomyopathy, valvular heart disease, untreated coronary artery disease)

          -  Left atrial diameter&gt;60mm

          -  Left atrial thromb or left atrial appendage thromb

          -  Pleural or pericardial adhesion

          -  Chronic obstructive pulmonary disease (COPD) (Forced expiratory volume in 1 second
             (FEV1)/Forced vital capacity (FVC)&lt;70%„ÄÅFEV1&lt;50% anticipated value)

          -  Secondary AF (eg. hyperthyroidism)

          -  Bilateral carotid artery stenosis&gt;80%

          -  Refuse to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Zhe, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <phone>86-10-88396051</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haojie Li, MD</last_name>
    <phone>86-10-88322317</phone>
    <email>lihaojiefuwai@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China National Center for Cardiovascular Diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Zheng, M.D., Ph.D.</last_name>
      <phone>8610-8839-6051</phone>
      <email>zhengzhefuwai@tom.com</email>
    </contact>
    <investigator>
      <last_name>Zhe Zheng, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hybrid ablation</keyword>
  <keyword>Thoracoscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

